Evidence map›Paper›PMID 34063593›Full record

ArticlePharmaceutics2021

Novel Self-Nano-Emulsifying Drug Delivery Systems Containing Astaxanthin for Topical Skin Delivery.

Thellie Ponto, Gemma Latter, Giuseppe Luna, Vânia R Leite-Silva, Anthony Wright, Heather A E Benson

Open access · goldAbstract read
In one paragraph

Article in Pharmaceutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 49 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Microbial astaxanthin: from bioprocessing to the market recognition.Applied microbiology and biotechnology · 2023
    Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Thellie PontoCurtin Medical School, Curtin Health Innovation Research Institute (CHIRI), Curtin University, GPO Box U1987, Perth, WA 6845, Australia.
Gemma LatterCurtin Medical School, Curtin Health Innovation Research Institute (CHIRI), Curtin University, GPO Box U1987, Perth, WA 6845, Australia.ORCID 0000-0002-5395-2246
Giuseppe LunaCurtin Medical School, Curtin Health Innovation Research Institute (CHIRI), Curtin University, GPO Box U1987, Perth, WA 6845, Australia.
Vânia R Leite-SilvaInstituto de Ciências Ambientais, Químicas e Farmacêuticas, Departamento de Ciências Farmacêuticas, Universidade Federal de São Paulo, UNIFESP-Diadema, São Paulo 09913-030, Brazil.
Anthony WrightSchool of Allied Health, Curtin University, GPO Box U1987, Perth, WA 6845, Australia.ORCID 0000-0002-0289-6141
Heather A E BensonCurtin Medical School, Curtin Health Innovation Research Institute (CHIRI), Curtin University, GPO Box U1987, Perth, WA 6845, Australia.ORCID 0000-0002-1818-5627
Curtin University · AUInstituto de Ciências Farmacêuticas · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Astaxanthin (ASX) is a potent lipophilic antioxidant derived from the natural pigment that gives marine animals their distinctive red-orange colour and confers protection from ultraviolet radiation. Self nano-emulsifying drug delivery systems (SNEDDS) have been successfully developed and evaluated to increase the skin penetration of ASX and target its antioxidant and anti-inflammatory potential to the epidermis and dermis. SNEDDS were prepared using a low-temperature spontaneous emulsification method, and their physical characteristics, stability, antioxidant activity, and skin penetration were characterized. Terpenes (D-limonene, geraniol, and farnesol) were included in the SNEDDS formulations to evaluate their potential skin penetration enhancement. An HPLC assay was developed that allowed ASX recovery from skin tissues and quantification. All SNEDDS formulations had droplets in the 20 nm range, with low polydispersity. ASX stability over 28 days storage in light and dark conditions was improved and antioxidant activity was high. SNEDDS-L1 (no terpene) gave significantly increased ASX penetration to the stratum corneum (SC) and the epidermis-dermis-follicle region (E + D + F) compared to an ASX in oil solution and a commercial ASX facial serum product. The SNEDDS-containing D-limonene gave the highest ASX permeation enhancement, with 3.34- and 3.79-fold the amount in the SC and E + D + F, respectively, compared to a similar applied dose of ASX in oil. We concluded that SNEDDS provide an effective formulation strategy for enhanced skin penetration of a highly lipophilic molecule, and when applied to ASX, have the potential to provide topical formulations for UV protection, anti-aging, and inflammatory conditions of the skin.

Indexed as

antioxidantcosmeceuticaldermatologicalnano-deliverypenetration enhancementskin targetingSNEDDSterpenes

Identifiers

PMID34063593
PMCPMC8147608
OpenAlexW3158171619

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.